HEPATITIS C VIRUS INHIBITORS

摘要

The invention provides compounds of formulas (I) or (II):;;wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

主权项

1. A compound of formula (I):wherein
W is selected from G is R1 is selected from C1-6alkyl, C1-6alkoxy, phenyl, C3-6cycloalkyl, heterocycle, and heteroaryl, wherein C1-6alkyl is optionally substituted with —ORa, amino, —SRe, heterocycle, or heteroaryl, C1-6alkoxy is optionally substituted with —ORa, and heterocycle is optionally substituted with —ORa, amino, or —C(O)OC1-6alkyl, or with one or two C1-3alkyl; R2 is selected from hydrogen and C1-6alkyl; R3 is selected from hydrogen, C-6alkyl, —C(O)OC1-6alkyl, —C(O)NRbRc, —C(O)C3-6cycloalkyl, and —S(O)2C1-3alkyl; R4 is selected from C1-6alkyl, C3-6cycloalkyl, and halo; R6 is independently selected from hydrogen, C1-6alkyl, and halo; R7 is selected from halo, C1-3alkyl, and C1-3alkoxy wherein C1-3alkyl and C1-3alkoxy are optionally substituted with one, two, three, four, or five halo; R8 is C1-3alkyl, optionally substituted with —ORd; R9 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —NRfRg, heteroaryl, heterocycle, and —CH2-heteroaryl;
wherein:C1-6alkyl is optionally substituted with one or two substituents independently selected from —ORh, —NRjRk, —NHC(O)C1-3alkyl, —NHC(O)C3-6cycloalkyl, and —NHC(O)OC1-3alkyl;C1-6alkoxy is optionally substituted with —ORh;any C3-6cycloalkyl is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, —ORh, and —CD3;any heterocycle is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, —C(O)OC1-3alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —C(O)NHC1-6alkyl, and —C(O)NHC3-6cycloalkyl;
wherein any —C(O)C1-6alkyl is optionally substituted with —NHC(O)OC1-3alkyl, —ORh or —NRjRk,any heteroaryl is optionally substituted with one or two C1-3alkyl; Ra, Rb, Rc, Rd, Re, Rf, Rh, Rj, and Rk are each independently hydrogen or C1-3alkyl; Rg is selected from hydrogen, C1-6alkyl, and C3-6cycloalkyl; R10 is hydrogen, halo, or C1-3alkyl substituted with one, two, or three halo or with —ORd; R11 is selected from hydrogen, C1-6alkyl, and halo; R12 is hydrogen, or R11 and R12 taken together form —CH2—; Am is —NHC(O)— or —C(O)NH— a is 0, 1, or 2; and b is 0, 1 or 2; or a pharmaceutically-acceptable salt or stereoisomer thereof.